Successful Management of Ectopic Adrenocorticotropin-Secreting Thymic Carcinoid With Mitotane: A New Look at an Old Drug
JCEM Case Reports · 23.02.2026 · 4 (3)
DOI: 10.1210/jcemcr/luaf334 ↗Kurz gefasst
Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 27.02.2026. Verfasst von Xiang Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Ectopic adrenocorticotropin syndrome (EAS) is usually associated with severe multiple complications and high mortality. Several adrenal steroidogenesis inhibitors can be used to control hypercortisolism when curative surgery is not feasible, but with different availability worldwide. It was long considered that mitotane (MTT) was not suitable for severe Cushing syndrome (CS) due to its delayed onset of action. We present a case of a 17-year-old girl with rapid-onset CS and an extremely high 24-hour urinary free cortisol (UFC) level (>300 times the upper limit of normal). An anterior mediastinal nodule with contrast enhancement was identified in computed tomography, with positive 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography with computed tomography (PET/CT) uptake (maximum standardized uptake value = 10.1), suggestive of a thymic neuroendocrine tumor as the most likely cause of EAS. Preoperative MTT monotherapy titrated to 2 g/day reduced UFC by 85% within 13 days without adverse effects, stabilized severe neuropsychiatric disturbances and opportunistic infections, thus enabling successful thymectomy. The tumor turned out to be an adrenocorticotropin-secreting thymic typical carcinoid. Other EAS cases treated with MTT reported in the literature were reviewed, and the time needed to control hypercortisolism using MTT was shorter than previously reported. Instead of an “add-on drug,” we should reconsider the role of MTT in the treatment of severe hypercortisolism in EAS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, Ch…
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
- Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
- Department of Endocrinology, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an 710004, China.
ORCID-Profile: Xiang Zhou, Lin Lu
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Zhou, X., Xu, Y., Peng, X., Hu, R., & Lu, L. (2026). Successful Management of Ectopic Adrenocorticotropin-Secreting Thymic Carcinoid With Mitotane: A New Look at an Old Drug. JCEM Case Reports, 4(3). https://doi.org/10.1210/jcemcr/luaf334
Vancouver
Zhou X, Xu Y, Peng X, Hu R, Lu L. Successful Management of Ectopic Adrenocorticotropin-Secreting Thymic Carcinoid With Mitotane: A New Look at an Old Drug. JCEM Case Reports. 2026;4(3). doi:10.1210/jcemcr/luaf334
BibTeX
@article{Zhou2026,
author = {Zhou, Xiang and Xu, Yuan and Peng, Xingtong and Hu, Ruijie and Lu, Lin},
title = {Successful Management of Ectopic Adrenocorticotropin-Secreting Thymic Carcinoid With Mitotane: A New Look at an Old Drug},
journal = {JCEM Case Reports},
year = {2026},
volume = {4},
number = {3},
doi = {10.1210/jcemcr/luaf334}
}
EUVIMED